Patient characteristics
| Number | Age | Sex | Rituximab infusion regimen | Time between t1and t2 (weeks) | Diagnosis |
|---|---|---|---|---|---|
| MALT, mucosa-associated lymphoid tissue; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; SLE, systemic erythematosus; t1 = before rituximab infusion; t2 = 7–17 weeks after rituximab infusion (mean 12 weeks). | |||||
| 1 | 25 | F | 2×1 g (W0, 2) | 9 | SLE |
| 2 | 59 | F | 4×375 mg/m2 (W0, 1, 2, 3) | 11 | pSS+MALT |
| 3 | 57 | F | 2×1 g (W0, 2) | 7 | pSS |
| 4 | 49 | F | 2×1 g (W0, 2) | 15 | RA |
| 5 | 31 | M | 4×375 mg/m2 (W0, 1, 2, 3) | 17 | SLE |